Why the study?
To better understand patient heterogeneity in fatty liver disease, MAFLD was proposed as a new nomenclature for NAFLD, motivating evaluation of cardiovascular risk across FLD subtypes.
Do different subtypes of metabolic dysfunction-associated fatty liver disease (MAFLD) increase cardiovascular risk assessed by epicardial adipose tissue and coronary artery calcium compared to patients without fatty liver disease or metabolic dysfunction?
Population
370 patients with or without FLD
Comparison
FLD subtypes and non-FLD with MD vs patients without FLD nor MD
Design
Cross-sectional study
Authors
Loading...
MAFLD-T2D/MUHO may flag higher CVD risk via EAT/CAC; hypothesis-generating and should not yet change practice.
Do different subtypes of metabolic dysfunction-associated fatty liver disease (MAFLD) increase cardiovascular risk assessed by epicardial adipose tissue and coronary artery calcium compared to patients without fatty liver disease or metabolic dysfunction?
MAFLD phenotypes, particularly those with type 2 diabetes or metabolically unhealthy obesity, are associated with significantly increased cardiovascular risk as measured by epicardial adipose tissue and coronary artery calcium.
Perdomo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: